Bolt Biotherapeutics (BOLT): Director received 2,763.83 units

2,763.83

Derivative units

Traded

Oct 23, 2026

Filed

Oct 27, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 16, 2026Insider · 3 peopleInsiders: 3 sales (~$16K)
2. Sep 17, 2026Insider · 3 peopleInsiders: 3 sales (~$48K)
3. Sep 18, 2026Insider · 3 peopleInsiders: 3 sales (~$65K)
4. Oct 1, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
5. Oct 23, 2026Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and changed a top executive or board member (and 6 more items)“Appointment of Director In accordance with the Merger Agreement, on October 23, 2026, effective immediately after the First Effective Time, Dr. Sheila Gujrathi was appointed to the Board as a Class II director of the Board.”

What came next

1. Nov 6, 20265% stakeCoastlands Capital LP reported a passive stake (13G) of 17.5%
2. Nov 9, 2026Insider · Bought outside the usual window10% owner purchased ~$319K of BOLT shares in the open market
3. Nov 12, 2026Company filing · Form 8-K · ResultsReported its results
4. Nov 12, 20265% stakeRenaissance Technologies LLC reported a passive stake (13G) of 4.8%

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Bolt Biotherapeutics

For Bolt Biotherapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BOLT page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Bolt Biotherapeutics

• SEC Schedule 13GNov 12, 2026
• SEC Form 4Nov 10, 2026
• SEC Schedule 13GNov 6, 2026
• SEC Form 4Sep 22, 2026
• SEC Form 4Sep 22, 2026
• SEC Form 4Sep 22, 2026

Everything OQRO holds on this company is on its BOLT page.